Crosaz Odile, Bonati Silvia, Briand Amaury, Chapelle Elodie, Cochet-Faivre Noëlle, Ka Diane, Darmon-Hadjaje Céline, Varloud Marie, Guillot Jacques
Department of Parasitology, Mycology and Dermatology, CHUVA, École nationale vétérinaire d'Alfort, UPE, 7 avenue du Général de Gaulle, 94704, Maisons-Alfort, France.
, Ceva Santé Animale, 10 avenue de la Ballastière, 33500, Libourne, France.
Parasit Vectors. 2017 Aug 23;10(1):392. doi: 10.1186/s13071-017-2335-x.
The present study assessed the activity of a combination of dinotefuran and pyriproxyfen (Vectra® Felis) for long-term control (3 months) of allergic dermatitis (AD) in privately-owned cats under common household conditions in Ile-de-France region.
This was an open pre-treatment vs post-treatment study. Twenty-eight client-owned cats with clinical signs of AD were enrolled in the study. They received topical application of the combination of dinotefuran and pyriproxyfen on days 0, 28, 56 and 84. Two parameters (clinical signs and pruritus severity) were used to assess the animals' condition on days 0, 28 and 84. Fleas were counted if they were observed.
Of the 28 cats initially enrolled, 26 were presented on day 28 and 20 for the final evaluation on day 84. A significant improvement in clinical signs and pruritus was observed in cats for which fleas and/or flea feces were detected on day 0. Globally, the post-treatment AD clinical scores on days 28 and 84 were different from that of the pre-treatment on day 0, with a reduction of 30% and 71%, respectively. For cats with fleas and/or flea feces, the reduction on days 28 and 84 was 33% and 85%, respectively. The improvement of clinical signs and pruritus was not significant in cats with no visible fleas and no flea feces at the beginning of the trial (n = 8).
The present study indicated that the treatment with a combination of dinotefuran and pyriproxyfen should be considered as useful in controlling fleas on cats without additional environmental treatment and useful for long-term control of clinical signs and pruritus in allergic cats.
本研究评估了呋虫胺和吡丙醚组合制剂（Vectra® Felis）在法国岛地区普通家庭环境下对宠物猫过敏性皮炎（AD）进行长期控制（3个月）的效果。
这是一项开放性的治疗前与治疗后对照研究。28只出现AD临床症状的宠物猫被纳入研究。在第0、28、56和84天对它们进行呋虫胺和吡丙醚组合制剂的局部给药。在第0、28和84天，使用两个参数（临床症状和瘙痒严重程度）评估动物的状况。若观察到跳蚤，则进行计数。
最初纳入的28只猫中，26只在第28天进行了评估，20只在第84天进行了最终评估。在第0天检测到跳蚤和/或跳蚤粪便的猫中，临床症状和瘙痒情况有显著改善。总体而言，治疗后第28天和第84天的AD临床评分与治疗前第0天不同，分别降低了30%和71%。对于有跳蚤和/或跳蚤粪便的猫，第28天和第84天的降低幅度分别为33%和85%。在试验开始时没有可见跳蚤和跳蚤粪便的猫（n = 8）中，临床症状和瘙痒的改善不显著。
本研究表明，在不进行额外环境处理的情况下，呋虫胺和吡丙醚组合制剂治疗对控制猫身上的跳蚤有效，且对过敏性猫的临床症状和瘙痒进行长期控制也有效。
